Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Melisko on the Role of Neoadjuvant Chemotherapy in ER+ Cancer

Michelle E. Melisko, MD
Published: Friday, Oct 27, 2017


Michelle E. Melisko, MD, a clinical professor of medicine, University of California, San Francisco (UCSF), discusses the role of neoadjuvant chemotherapy in estrogen receptor (ER)-positive breast cancer.

Neoadjuvant treatment is adventitious for some patients who have large tumors, node-positive tumors, or biologically high-risk cancers.

UCSF conducted a clinical trial, I-SPY, which looked at neoadjuvant chemotherapy in combination with experimental therapies to try to improve the rates of pathologic complete response.

ER-positive diseases rarely achieve a pathologic complete response, so chemotherapy may not be best for this patient population, explains Melisko. Neoadjuvant endocrine therapy, especially in combination with biological therapies such as CDK4/6 inhibitors, may be a better approach for patients who are ER-positive, says Melisko.

Michelle E. Melisko, MD, a clinical professor of medicine, University of California, San Francisco (UCSF), discusses the role of neoadjuvant chemotherapy in estrogen receptor (ER)-positive breast cancer.

Neoadjuvant treatment is adventitious for some patients who have large tumors, node-positive tumors, or biologically high-risk cancers.

UCSF conducted a clinical trial, I-SPY, which looked at neoadjuvant chemotherapy in combination with experimental therapies to try to improve the rates of pathologic complete response.

ER-positive diseases rarely achieve a pathologic complete response, so chemotherapy may not be best for this patient population, explains Melisko. Neoadjuvant endocrine therapy, especially in combination with biological therapies such as CDK4/6 inhibitors, may be a better approach for patients who are ER-positive, says Melisko.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x